2 ASX growth shares I'd buy over Nvidia

I'd rather back these ASX leaders.

| More on:
a mature but cool older woman holds a watering can and tends to a healthy green plant growing up the wall in her house.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

In this article, I'm going to talk about two ASX growth shares that seem better value to me than NVIDIA Corp (NASDAQ: NVDA) shares.

Nvidia has gone on an incredible run, up more than 210% this year and around 300% from mid-October. There aren't many shares that have made those sorts of returns in less than a year, let alone by a business that's now worth over US$1 trillion.

There's a lot of hype surrounding artificial intelligence (AI), and while Nvidia seems on course to benefit from the large demand, its current valuation has a lot of growth factored into the market capitalisation.

I believe the two ASX growth shares that I'm going to write about are more compelling and don't have global attention.

Volpara Health Technologies Ltd (ASX: VHT)

Volpara describes itself as a business that makes software to save families from cancer. The technology is used to "better understand cancer risk, empower patients in personal care decision, improve and maintain quality, and guide recommendations about additional imaging, genetic testing, and other interventions."

The idea is that AI-powered image analysis enables radiologists to quantify breast tissue with precision. Volpara notes that one of its selling points is that in an industry facing increasing staff shortages, its software helps streamline operations.

Since February 2021, the Volpara share price has fallen over 50%, yet the ASX growth share has made a lot of progress. In FY23, it generated 34% revenue growth to NZ$35 million, while gross profit increased 36% to NZ$32.4 million. This implies a very high gross profit margin, which I love to see for businesses that are growing revenue.

When a business has a high gross profit margin it means that a lot of the new revenue can turn into usable profit and then be used for more growth or to increase the profit margin. Normalised earnings before interest, tax, depreciation and amortisation (EBITDA) improved by 57% to a loss of NZ$6.1 million.

I think there is a lot of potential for the business to grow revenue with more of its software being utilised by healthcare professionals and geographic expansion in places like Europe.

Johns Lyng Group Ltd (ASX: JLG)

Johns Lyng describes itself as an integrated building service, specialising in rebuilding and restoring a variety of properties and contents after damage by insured events, including impact, weather and fire events.

There seems to be a disappointing trend that there are more damaging and expensive weather events, which can be a tailwind for the level of the company's work and earnings.

FY23 saw the ASX growth share's total revenue rise 43.2% to $1.28 billion, while overall net profit after tax (NPAT) jumped 64.3%. The catastrophe-related segment saw revenue soar 125.3% to $371.3 million.

In FY24, the company is expecting its 'business as usual' revenue to increase by another 18.5%, while the 'business as usual' EBITDA is predicted to increase by 20.1% to $113 million.

I like that the business is looking to grow in different areas as well, including its move into strata/body corporate services, as well as 'essential home services', such as smoke alarm, electrical, gas compliance, testing and maintenance services. There are a lot of revenue synergies that could be created between Johns Lyng's businesses, as well as providing plenty of acquisition opportunities.

According to Commsec, the Johns Lyng share price is valued at 26 times FY25's estimated earnings.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Johns Lyng Group and Volpara Health Technologies. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Nvidia. The Motley Fool Australia has positions in and has recommended Volpara Health Technologies. The Motley Fool Australia has recommended Johns Lyng Group and Nvidia. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

A fit woman in workout gear flexes her muscles with two bigger people flexing behind her, indicating growth.
Growth Shares

3 monster stocks to hold for the next 3 years

These 3 ASX shares operate in different industries and could be worth holding for long-term growth over the next 3…

Read more »

Person pointing at an increasing blue graph which represents a rising share price.
Growth Shares

2 ASX growth shares to snap up while they're still down

Brokers see plenty of upside for these mainstay sector picks.

Read more »

Man pointing an upward line on a bar graph symbolising a rising share price.
Growth Shares

Why these ASX growth stocks could be much bigger in 2030 than today

These stocks have long growth runways and strong business models.

Read more »

A woman sits at her computer with her hand to her mouth and a contemplative smile on her face as she reads about the performance of Allkem shares on her computer
Growth Shares

3 incredible ASX growth shares to buy and hold forever in 2026

True long-term investing means owning businesses you’d be happy to hold through volatility, uncertainty, and decades of change.

Read more »

Happy work colleagues give each other a fist pump.
Growth Shares

2 shares to buy hand over fist before the ASX 200 soars higher in 2026

These shares are highly rated by brokers for a reason. Here's what you need to know about them.

Read more »

Buy now written on a red key with a shopping trolley on an Apple keyboard.
Broker Notes

Experts rate these 2 ASX shares as buys this month!

Leading analysts say these stocks are a buy.

Read more »

Happy healthcare workers in a labs
Technology Shares

Prediction: CSL shares could soar past $270 in 2026

Here's what to expect from the Australian-based global biotechnology company this year.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
Growth Shares

2 unstoppable ASX 200 stocks to buy in 2026 and hold forever

These blue chips could have very bright futures. Do you own them?

Read more »